Ideal patient selection for a deferred cytoreductive nephrectomy should include an assessment of Memorial Sloan Kettering Cancer Center risk score, according to investigators. Among patients with ...

Three risk categories for predicting survival of patients refractory to a first-line cytokine treatment were identified at Memorial Sloan Kettering Cancer Centre (‘MSKCC score’) on the basis ...

The MSKCC prognostic score and its modifications have subsequently become a standard by which RCC patients have been assessed and stratified prior to enrollment into clinical trials of targeted ...

Several factors in patients with clear cell renal cell carcinoma are associated with a diminished response to immune checkpoint inhibition (ICI). ... Link to MSKCC Score a Mystery.

Single RCC Bone Metastasis Predicts Better Survival. Jody A. Charnow | February 18, 2017 . Bone surgery should be considered in patients with solitary bone metastasis and no concomitant ...

Recent research from a collaborative team at Memorial Sloan Kettering found that more than 20% of people with this type of RCC have disease that is driven by inherited cancer mutations. Many of the ...

Methods: Between 1995 and 2005, 214 patients with recurrent RCC were the subjects of this retrospective analysis. At recurrence, MSKCC risk classification was used to classify patients as being at ...

Yi et al retrospectively studied the ability of the MSKCC nomogram to predict 5- and 10-year ipsilateral breast tumor recurrence after local excision of DCIS and concluded that the score had ...

Background: The modified Glasgow prognostic score (mGPS) is a pre-treatment prognostic system based on inflammatory biomarkers that is comparable in accuracy to the Memorial Sloan-Kettering Cancer ...

Temsirolimus was approved in Europe as first-line treatment of poor-prognosis advanced renal cell carcinoma (advRCC) based on significant clinical benefits. Patients with advRCC and multiple poor ...

Meeting Coverage > IKCS mRCC Agents: Similar Outcomes in Cross-Trial Comparison — PFS, OS not that different between axitinib and cabozantinib ...